Non-Small Cell Lung Cancer (NSCLC)

OptiTROP-Lung04 data show sacituzumab tirumotecan cut the risk of progression or death by 51% in patients with nonsquamous EGFR-mutated NSCLC resistant to EGFR TKIs.

The SKYSCRAPER-03 trial revealed that tiragolumab plus atezolizumab failed to improve progression-free survival compared with durvalumab in NSCLC.

Osimertinib plus chemotherapy significantly improved overall survival in EGFR-mutated NSCLC, outperforming monotherapy across various prognostic factors.

Osimertinib and local consolidative therapy was a safe and effective strategy to extend disease control in patients with advanced EGFR-mutant NSCLC.

Alectinib shows promising long-term survival benefits over crizotinib for advanced ALK-positive NSCLC, highlighting significant clinical advancements.

Sevabertinib monotherapy was deemed tolerable across various cohorts of patients who were pretreated and treatment-naïve with HER2-mutant advanced NSCLC.

Results from the Beamion LUNG-1 study showed that first-line zongertinib yielded continued benefit for patients with HER2-mutated NSCLC.

The safety profile of durvalumab after radiotherapy was consistent with durvalumab after chemoradiotherapy among those with unresectable stage III NSCLC.

Panelists discuss how the field is shifting from reactive to proactive management of dermatologic adverse events, with future developments potentially including new topical treatments and integrated dermatology support within oncology practices.

Treatment-related AEs with sunvozertinib were consistent with EGFR tyrosine kinase inhibitors in patients with NSCLC with EGFR exon 20 insertion mutations.

Panelists discuss how the COCOON regimen's tolerability and effectiveness in reducing dose interruptions will improve patient experience and outcomes, requiring substantial nursing support and patient education for successful implementation in clinical practice.

Panelists discuss how the COCOON study demonstrated a significant reduction in grade 2 or higher dermatologic adverse events from 73% to 41%, with particularly notable improvements in face, body, and scalp rashes while maintaining comparable response rates.

Long-term data from the STARS trial affirm stereotactic radiation as a strong alternative to surgery for patients with operable stage I NSCLC.

The efficacy of TTFields was greater among patients who received immune checkpoint inhibition for the treatment of brain metastatic NSCLC.

Experts at City of Hope explore innovative immunotherapy strategies for non-small cell lung cancer, highlighting efficacy and toxicity management in treatment.

Panelists discuss how the COCOON trial design represents a straightforward approach using standard practice medications, though implementation challenges include patient compliance with the complex 4-drug regimen requiring significant education and support staff involvement.

An expert discusses the vital role of comprehensive genomic profiling in personalizing treatment for non-small cell lung cancer, enhancing patient outcomes.

Panelists discuss how the COCOON study randomly assigned patients to either standard care or proactive dermatologic management using prophylactic antibiotics, topical treatments, skin moisturization, and anticoagulation to reduce grade 2 or higher dermatologic adverse events.

Experts discuss evolving therapies for EGFR-mutated metastatic NSCLC, comparing combination regimens and their impact on patient outcomes.

Explore the latest advancements in c-Met-targeted therapies for NSCLC, including optimal testing strategies and management of adverse events.

Panelists discuss how dermatologic adverse events with EGFR inhibitors are more severe than previously seen with third-generation tyrosine kinase inhibitors, requiring reactive management strategies including topical steroids, antibiotics, and dermatologic consultations that are often difficult to obtain.

Panelists discuss how patients with EGFR-mutated non–small cell lung cancer develop dermatologic adverse events with amivantamab treatment, presenting as papules, pustules, and paronychia that significantly impact quality of life.

The decision from the Ministry of Health, Labour and Welfare was supported by phase 3 LUNAR trial results showing an OS benefit with Optune Lua in NSCLC.

Ateganosine plus cemiplimab was well tolerated in patients with heavily pretreated advanced NSCLC, with most adverse effects grades 1/2 in severity.

Full overall survival results with amivantamab plus lazertinib from the Asia cohort of the MARIPOSA trial will be shared at a future medical conference.